Wildner, Sabrina
Huber, Sara
Regl, Christof
Huber, Christian G. http://orcid.org/0000-0001-8358-1880
Lohrig, Urs
Gadermaier, Gabriele
Funding for this research was provided by:
Christian Doppler Forschungsgesellschaft (Christian Doppler Laboratory for Innovative Tools for Biosimilar Characterization, Christian Doppler Laboratory for Innovative Tools for Biosimilar Characterization)
Austrian Science Fund (P26125)
Article History
Received: 25 June 2018
Accepted: 16 November 2018
First Online: 1 February 2019
Competing Interests
: Novartis and Thermo Fisher Scientific GmbH provide financial support for the Christian Doppler Laboratory for Innovative Tools for Biosimilar Characterization, Salzburg, Austria. The salary of S.W. was fully funded, C.G.H.’s salary is partly funded by the Christian Doppler Laboratory for Biosimilar Characterization. U.L. is employee of Sandoz GmbH. Sandoz GmbH has obtained EMA licensing for its proposed biosimilar GP2013 which is currently marketed under the brand name Rixathon® in the E.U. The authors declare no other competing interest. S.H., C.R. and G.G. have no conflict of interest.